Stem Cell Therapy finalizes merger with South Korean firm

02/1/2010 | American City Business Journals

Stem Cell Therapy International has completed its merger with South Korean firm Histostem in a deal that will allow it to run Histostem as its wholly owned unit. Stem Cell Therapy, a provider of biological supplies containing new stem cell product lines, plans to operate under the name AmStem.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL